Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion

British Journal of Dermatology

Volumn 157, Issue 1, 2007, Pages 142-148

  Fardet, L ^a,b   Flahault, A ^b   Kettaneh, A ^a   Tiev, K P ^a   Genereau T ^c   Toledano C ^a   Lebbe C ^d   Cabane, J ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

^c Nouvelles Cliniques Nantaises   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Adverse events; Corticosteroids

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLORAZEPATE POTASSIUM; CORTICOSTEROID; PREDNISONE; VITAMIN D;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; AGED; ANXIETY; ARTICLE; CAPILLARY RESISTANCE; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEPRESSION; DISABILITY; DRUG MEGADOSE; DYSPHONIA; EPIGASTRIC PAIN; EUPHORIA; FEMALE; FLUSHING; GIANT CELL ARTERITIS; HAND TREMOR; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERPHAGIA; HYPERTENSION; ICHTHYOSIS; INCIDENCE; INSOMNIA; IRRITABILITY; LIPODYSTROPHY; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL DOCUMENTATION; MENSTRUATION DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SARCOIDOSIS; SELF CONCEPT; SIDE EFFECT; SKIN DISEASE; SWELLING; VASCULITIS; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ATTITUDE TO HEALTH; COHORT STUDIES; FEMALE; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PREDNISONE; RISK FACTORS; TEMPORAL ARTERITIS;

EID: 34250631652     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07950.x     Document Type: Article

References (51)

1. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004 19 : 893 9.
2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002 13 : 777 87.
3. Homik JE, Cranney A, Shea B et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999 26 : 1148 57.
4. Delcourt C, Cristol JP, Tessier F et al. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. Pathologies Oculaires Liees a l'Age. Am J Epidemiol 2000 151 : 497 504.
5. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997 350 : 979 82.
6. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax 1968 23 : 571 81.
7. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972 49 : 329 36.
8. Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology 1984 30 : 60 5.
9. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965 48 : 287 90.
10. Akerkar GA, Peppercorn MA, Hamel MB et al. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol 1997 92 : 461 64.
11. Saag KG, Koehnke R, Caldwell JR et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994 96 : 115 23.
12. Walsh LJ, Wong CA, Pringle M et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996 313 : 344 6.
13. Batchelor TT, Taylor LP, Thaler HT et al. Steroid myopathy in cancer patients. Neurology 1997 48 : 1234 38.
14. Kirwan JR, Hallgren R, Mielants H et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004 63 : 688 95.
15. Chibane S, Feldman-Billard S, Rossignol I et al. [Short-term tolerance of three days pulse methylprednisolone therapy: a prospective study in 146 patients]. Rev Med Interne 2005 26 : 20 6.
16. Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001 44 : 814 17.
17. Mignogna MD, Lo Muzio L, Ruoppo E et al. High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med 2002 31 : 339 44.
18. Boston Collaborative Drug Study. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972 13 : 694 98.
19. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002 136 : 1 12.
20. Bar-Meir S, Chowers Y, Lavy A et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998 115 : 835 40.
21. Campieri M, Ferguson A, Doe W et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997 41 : 209 14.
22. Sato A, Funder JW, Okubo M et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995 8 : 823 28.
23. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005 352 : 48 62.
24. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003 17 (Suppl. 1 S141 8.
25. Hall RC, Popkin MK, Stickney SK et al. Presentation of the steroid psychoses. J Nerv Ment Dis 1979 167 : 229 36.
26. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001 153 : 1089 93.
27. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000 27 : 1668 73.
28. Messer J, Reitman D, Sacks HS et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983 309 : 21 4.
29. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994 236 : 619 32.
30. Gabriel SE, Sunku J, Salvarani C et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 40 : 1873 78.
31. Caporali R, Cimmino MA, Ferraccioli G et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004 141 : 493 500.
32. Walsh LJ, Wong CA, Oborne J et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001 56 : 279 84.
33. Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981 61 (Suppl. 7 381s 3s.
34. Rizzato G, Riboldi A, Imbimbo B et al. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med 1997 91 : 449 60.
35. Kelly JJ, Mangos G, Williamson PM et al. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998 25 : S51 6.
36. Whitworth JA, Schyvens CG, Zhang Y et al. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001 28 : 993 96.
37. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 96 : 23 43.
38. Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest 1995 18 : 586 91.
39. Urban RC Jr., Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986 31 : 102 10.
40. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995 54 : 49 52.
41. McEvoy CE, Ensrud KE, Bender E et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 157 (3 Pt 1 704 9.
42. LoCascio V, Bonucci E, Imbimbo B et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990 8 : 39 51.
43. Laan RF, van Riel PL, van de Putte LB et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993 119 : 963 68.
44. Goldstein MF, Fallon JJ Jr., Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999 116 : 1733 49.
45. Bell R, Carr A, Thompson P. Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond 1997 31 : 158 61.
46. Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000 25 : 227 34.
47. Yood RA, Harrold LR, Fish L et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 2001 161 : 1322 27.
48. Population Reference Bureau. Available at: http://www.prb.org (accessed on 31 January 2007).
49. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003 42 : 1247 50.
50. Bae SC, Corzillius M, Kuntz KM et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003 42 : 46 53.
51. Pisu M, James N, Sampsel S et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005 44 : 781 88.